Oxford Ventures Inc auf dem Weg zum Cent $$$$$$$$$$$$$$$$$$$ - 500 Beiträge pro Seite
eröffnet am 28.10.05 17:53:40 von
neuester Beitrag 30.10.05 22:20:29 von
neuester Beitrag 30.10.05 22:20:29 von
Beiträge: 14
ID: 1.016.375
ID: 1.016.375
Aufrufe heute: 0
Gesamt: 499
Gesamt: 499
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 1 Stunde | 5008 | |
| vor 50 Minuten | 4074 | |
| vor 49 Minuten | 3221 | |
| vor 1 Stunde | 2732 | |
| vor 56 Minuten | 2111 | |
| heute 08:50 | 1879 | |
| vor 1 Stunde | 1463 | |
| heute 13:07 | 1292 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.073,99 | +0,80 | 240 | |||
| 2. | 3. | 0,1905 | +0,79 | 113 | |||
| 3. | 2. | 1,1000 | -20,29 | 107 | |||
| 4. | 5. | 9,2500 | +0,05 | 73 | |||
| 5. | 4. | 156,88 | -1,13 | 57 | |||
| 6. | 12. | 2.342,39 | +0,44 | 39 | |||
| 7. | Neu! | 11,905 | +14,97 | 37 | |||
| 8. | Neu! | 4,8890 | +9,01 | 36 |
Feedback
Oxford Ventures Inc oder an der OTCBB OXFV steht bei einem Umsatz von 27 Mio Aktien mit einem + von fast 50 % heute gut da. Grund ist der kauf einer Fa. Namens Urulu Inc die bereits ein profitabler Medizinhersteller ist. Weitere Infos folgen, aber ich glaub die sind schon 1-2 Wochen alt.... Nachdem der Wert in die Höhe geschossen ist hat er sich die letzten Wochen auf einem gesunden Niveau konsolidiert und geht jezt stetig in die Höhe auch ohne neue News.
Hier ist die Meldung
Oxford Ventures, Inc. Signs Definitive Merger Agreement to Acquire ULURU Inc.; Completes $13 million Convertible Debenture Offering; Enters $30 Million Standby Equity Distribution Agreement
Oxford Ventures, Inc. (OTC Bulletin Board : OXFV.OB)(" Oxford" ) today announced that it has signed a definitive merger agreement to acquire ULURU Inc. (" ULURU" ), a private Delaware company that focuses on advanced topical delivery of pharmaceutical agents. Separately, today ULURU announced the acquisition of the topical product assets of Access Pharmaceuticals, Inc. in a transaction valued at up to $20.7 million. Attached to this press release is a copy of the ULURU press release announcing the acquisition of the topical product assets.
Under the terms of the merger agreement, ULURU will become a wholly owned subsidiary of Oxford on the terms previously disclosed in our Form 8K filling with the Securities and Exchange Commission on September 13, 2005. In conjunction with the proposed acquisition, Oxford completed two financing transactions with an investor group including Highgate House Funds, Ltd. and Cornell Capital Partners LP. In the first transaction, Oxford has received a commitment for the sale of $15 million of secured convertible debentures, of which $13 million has been funded with the balance to be received upon the effectiveness of a registration statement filed with the Securities and Exchange Commission allowing for the resale of shares issued in connection with a Standby Equity Distribution Agreement. In the second financing, Oxford entered into a Standby Equity Distribution Agreement for up to $30 million.
Commenting on the recent developments, Daniel Leonard, President & CEO of Oxford, stated, " We have evaluated numerous opportunities for the company and believe that this series of transactions gives our shareholders the best opportunity to maximize returns. ULURU offers exciting potential as it has a developing revenue base and technologies from which significant product opportunities may be developed
Oxford Ventures, Inc. Signs Definitive Merger Agreement to Acquire ULURU Inc.; Completes $13 million Convertible Debenture Offering; Enters $30 Million Standby Equity Distribution Agreement
Oxford Ventures, Inc. (OTC Bulletin Board : OXFV.OB)(" Oxford" ) today announced that it has signed a definitive merger agreement to acquire ULURU Inc. (" ULURU" ), a private Delaware company that focuses on advanced topical delivery of pharmaceutical agents. Separately, today ULURU announced the acquisition of the topical product assets of Access Pharmaceuticals, Inc. in a transaction valued at up to $20.7 million. Attached to this press release is a copy of the ULURU press release announcing the acquisition of the topical product assets.
Under the terms of the merger agreement, ULURU will become a wholly owned subsidiary of Oxford on the terms previously disclosed in our Form 8K filling with the Securities and Exchange Commission on September 13, 2005. In conjunction with the proposed acquisition, Oxford completed two financing transactions with an investor group including Highgate House Funds, Ltd. and Cornell Capital Partners LP. In the first transaction, Oxford has received a commitment for the sale of $15 million of secured convertible debentures, of which $13 million has been funded with the balance to be received upon the effectiveness of a registration statement filed with the Securities and Exchange Commission allowing for the resale of shares issued in connection with a Standby Equity Distribution Agreement. In the second financing, Oxford entered into a Standby Equity Distribution Agreement for up to $30 million.
Commenting on the recent developments, Daniel Leonard, President & CEO of Oxford, stated, " We have evaluated numerous opportunities for the company and believe that this series of transactions gives our shareholders the best opportunity to maximize returns. ULURU offers exciting potential as it has a developing revenue base and technologies from which significant product opportunities may be developed
Hier mal was zu Urulu
DALLAS--(HSMN NewsFeed)--Oct. 12, 2005--ULURU Inc., a private company established to develop a portfolio of advanced topical delivery technologies, today announced that it has purchased the topical product assets of Access Pharmaceuticals, Inc. (AMEX: AKC ). Additionally, ULURU Inc. signed a definitive merger agreement with Oxford Ventures, Inc. (" Oxford" ). Under the terms of the merger agreement ULURU Inc. will become a wholly owned subsidiary of Oxford on the terms previously disclosed by Oxford in a Form 8-K filling with the Securities and Exchange Commission on September 13, 2005.
The transaction value for the acquired assets is up to $20.7 million, with $8.7 million payable on closing, up to $3.7 million payable in 12 months, and $1 million payable on the achievement of a commercial milestone or 24 months, whichever occurs first. Additional payments of up to $7.3 million will be made on the achievement of development and commercial milestones.
The principal shareholder of ULURU Inc. is Kerry P. Gray, the former President and CEO of Access, who was instrumental in the development of the acquired technology. The products purchased include Aphthasol and OraDisc A, the FDA approved products for the treatment of canker sores, and Zindaclin, a product for the treatment of acne, approved and marketed in numerous European and global markets. In addition ULURU has acquired the OraDisc technology platform and a fully paid license for numerous applications of the nanoparticle aggregate technology.
Commenting on the transaction Kerry P. Gray, President and CEO of ULURU, stated, " The completion of this acquisition is the first step in the establishment of a company focused on advanced topical delivery technologies. Both of the acquired technologies have numerous applications, from which an extensive portfolio of products can be developed. OraDisc has the potential not only to deliver drugs to the mouth and tooth surface and oral cavity, but offers significant potential as a transmucosal drug delivery system. The initial focus of product development with the hydrogel nanoparticle aggregate technology will be in the areas of wound management, burn care and in the field of facial restoration as a dermal filler."
As part of the asset acquisition employees engaged in the development of these technologies will be transferred from Access to ULURU. Likewise, the physical assets associated with these technologies will be transferred to ULURU. In the short term ULURU will continue to operate in the current facility to enable an orderly business transfer.
Gray continued, " This is an important step towards the company establishing a marketing organization focused in niche markets including wound and burn care. We are actively looking for additional acquisitions in this area to rapidly establish a meaningful commercial operation in this market segment."
ULURU INC. is an emerging specialty pharmaceutical company dedicated to becoming a leading topical drug delivery and oral care company by developing products utilizing its innovative transmucosal delivery system and hydrogel nanoparticle aggregate technology and acquiring value-added topical products.
DALLAS--(HSMN NewsFeed)--Oct. 12, 2005--ULURU Inc., a private company established to develop a portfolio of advanced topical delivery technologies, today announced that it has purchased the topical product assets of Access Pharmaceuticals, Inc. (AMEX: AKC ). Additionally, ULURU Inc. signed a definitive merger agreement with Oxford Ventures, Inc. (" Oxford" ). Under the terms of the merger agreement ULURU Inc. will become a wholly owned subsidiary of Oxford on the terms previously disclosed by Oxford in a Form 8-K filling with the Securities and Exchange Commission on September 13, 2005.
The transaction value for the acquired assets is up to $20.7 million, with $8.7 million payable on closing, up to $3.7 million payable in 12 months, and $1 million payable on the achievement of a commercial milestone or 24 months, whichever occurs first. Additional payments of up to $7.3 million will be made on the achievement of development and commercial milestones.
The principal shareholder of ULURU Inc. is Kerry P. Gray, the former President and CEO of Access, who was instrumental in the development of the acquired technology. The products purchased include Aphthasol and OraDisc A, the FDA approved products for the treatment of canker sores, and Zindaclin, a product for the treatment of acne, approved and marketed in numerous European and global markets. In addition ULURU has acquired the OraDisc technology platform and a fully paid license for numerous applications of the nanoparticle aggregate technology.
Commenting on the transaction Kerry P. Gray, President and CEO of ULURU, stated, " The completion of this acquisition is the first step in the establishment of a company focused on advanced topical delivery technologies. Both of the acquired technologies have numerous applications, from which an extensive portfolio of products can be developed. OraDisc has the potential not only to deliver drugs to the mouth and tooth surface and oral cavity, but offers significant potential as a transmucosal drug delivery system. The initial focus of product development with the hydrogel nanoparticle aggregate technology will be in the areas of wound management, burn care and in the field of facial restoration as a dermal filler."
As part of the asset acquisition employees engaged in the development of these technologies will be transferred from Access to ULURU. Likewise, the physical assets associated with these technologies will be transferred to ULURU. In the short term ULURU will continue to operate in the current facility to enable an orderly business transfer.
Gray continued, " This is an important step towards the company establishing a marketing organization focused in niche markets including wound and burn care. We are actively looking for additional acquisitions in this area to rapidly establish a meaningful commercial operation in this market segment."
ULURU INC. is an emerging specialty pharmaceutical company dedicated to becoming a leading topical drug delivery and oral care company by developing products utilizing its innovative transmucosal delivery system and hydrogel nanoparticle aggregate technology and acquiring value-added topical products.
Das beste ist der Wert wurde noch gar nicht endeckt und erst seit 2 Wochen an der Berliner Börse gehandelt. Heute morgen gab es noch 400000 zu 0,004 jetzt sind es schon 0,005 bei US 0,0053. Naja Risiko halt....gele...........
Aha hier die News von heute.
Werde gleich mal die News in Deutsch zusammenfassen aber wenn ich es richtig verstanden habe mwollen die in den nächsten jahren in einen 3 billion $ markt einsteigen und dabei einen Umsatz von 500 Mio Dollar einfahren. und das bei einem Kurs von jetzt 0,005. Wenn das bekannt wird geht das Ding mal granatenmässig durch die Decke.
OXFORD VENTURES INC Quick Quote: OXFV 0.01 (+0.00)
ULURU Formed to Develop Innovative Oral and Topical Products; Commercialization Strategy Focused on Wound Management, Burn Care and Products for Facial Restoration
10/28/05
DALLAS, Oct 28, 2005 (BUSINESS WIRE) --
ULURU INC. ("ULURU"), is an emerging pharmaceutical company focused on the development of a portfolio of innovative topical delivery technologies to provide patients and consumers with an improved clinical outcome through controlled delivery. ULURU was formed to acquire the topical assets of Access Pharmaceuticals, Inc. and subsequently merge with Oxford Ventures, Inc. (OTC bulletin board: OXFV). The companies have now entered a definitive merger agreement.
ULURU plans to establish a commercial organization to market products in niche areas including wound management, burn care and facial restoration and plans to out-license products that fall outside the strategic focus of the commercial organization. Commercial partners will be sought to market all products in international markets.
The focus of our development and commercial activities with the nanoparticle aggregate technology is in three market segments, wound management, burn care and dermal fillers for facial restoration. These markets are currently projected to exceed $3 billion and are projected to expand substantially over the next five years. The technology development focus for wound management and burn care is directed towards producing protective film barrier dressings that will release drugs including antibiotics and pain medications. Innovative products in the wound management and burn care categories which can deliver drugs and require significantly less nursing care offer exciting potential.
The dermal filler market is a rapidly expanding category where currently available products degrade in a relatively short period requiring repeat procedures. A significant opportunity exists to develop a permanent sub-dermal filler to address the deep tissue problems associated with facial restoration. Developing such a product is ULURU`s focus, which presents us with a unique opportunity to lead the development of a market segment which we project will expand into a market that exceeds $500 million.
As part of the acquisition of the topical product assets of Access Pharamceuticals, Inc., the strategic partnerships associated with the acquired technologies were transferred to ULURU. An extensive network of licenses is in place to globally market our approved products, these alliances include:
Product Partner Territory ------- ------- ---------OraDisc- Benzocaine Wyeth Consumer Healthcare North AmericaOraDisc- Amlexanox Discus Dental United States Zambon Europe Esteve Spain, Portugal, Greece Meda AB Scandinavia ProStrakan UK Ireland EpiTan Australia / New Zealand Orient Europharma Asia
In addition ULURU`s product Zindaclin, a once daily treatment for acne, has been licensed worldwide to ProStrakan. In turn, ProStrakan has established an extensive network of sub-licensees to market the product globally, including Fujisawa, for certain European markets, Pliva for the Central Eastern Europe region and numerous additional licensees for smaller territories.
The licenses currently in place provide ULURU with licensing revenue on the achievement of certain development and commercial milestones of in excess of $15 million. Additionally, ULURU will receive royalty payments in the range of 5-15% on all worldwide sales.
In addition to ULURU`s current OraDisc products, amlexanox for the prevention and treatment of canker sores and benzocaine for oral pain, ULURU has prioritized tooth whitening, cough and cold and desensitizing teeth as the lead consumer product developments. Also, ULURU plans to develop a range of prescription products utilizing OraDisc as a transmucosal delivery device. Supportive cancer care products and migraine relief are the initial development focus.
Commenting on the status of the company, Kerry P. Gray President and CEO of ULURU stated, "Establishing a commercial operation centered on our innovative nanoparticle aggregate technology, which presents us with the opportunity to market numerous products to meet unmet medical needs, is an exciting opportunity. We anticipate that we will continue to expand our network of strategic partners. We are currently working with a number of major pharmaceutical companies who are evaluating our technology and conducting consumer market research. Utilizing our technology portfolio, we believe it is possible to rapidly and cost-effectively develop value-added products. Given the numerous applications of the technology, we believe that we have the opportunity to significantly increase revenue from licensing activities."
ULURU Inc. is an emerging, specialty pharmaceutical company focused on the development of a portfolio of topical delivery technologies to proved patients and consumers with an improved clinical outcome through controlled delivery utilizing its innovative transmucosal delivery system and hydrogel nanoparticle aggregate technology.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and involve risks and uncertainties, including but not limited to statements made relating to the business prospects of ULURU Inc., the potential for ULURU Inc. to secure and maintain strategic partners, licensing revenues to be received under existing agreements and development of product candidates. These statements are subject to numerous risks and uncertainties
Werde gleich mal die News in Deutsch zusammenfassen aber wenn ich es richtig verstanden habe mwollen die in den nächsten jahren in einen 3 billion $ markt einsteigen und dabei einen Umsatz von 500 Mio Dollar einfahren. und das bei einem Kurs von jetzt 0,005. Wenn das bekannt wird geht das Ding mal granatenmässig durch die Decke.
OXFORD VENTURES INC Quick Quote: OXFV 0.01 (+0.00)
ULURU Formed to Develop Innovative Oral and Topical Products; Commercialization Strategy Focused on Wound Management, Burn Care and Products for Facial Restoration
10/28/05
DALLAS, Oct 28, 2005 (BUSINESS WIRE) --
ULURU INC. ("ULURU"), is an emerging pharmaceutical company focused on the development of a portfolio of innovative topical delivery technologies to provide patients and consumers with an improved clinical outcome through controlled delivery. ULURU was formed to acquire the topical assets of Access Pharmaceuticals, Inc. and subsequently merge with Oxford Ventures, Inc. (OTC bulletin board: OXFV). The companies have now entered a definitive merger agreement.
ULURU plans to establish a commercial organization to market products in niche areas including wound management, burn care and facial restoration and plans to out-license products that fall outside the strategic focus of the commercial organization. Commercial partners will be sought to market all products in international markets.
The focus of our development and commercial activities with the nanoparticle aggregate technology is in three market segments, wound management, burn care and dermal fillers for facial restoration. These markets are currently projected to exceed $3 billion and are projected to expand substantially over the next five years. The technology development focus for wound management and burn care is directed towards producing protective film barrier dressings that will release drugs including antibiotics and pain medications. Innovative products in the wound management and burn care categories which can deliver drugs and require significantly less nursing care offer exciting potential.
The dermal filler market is a rapidly expanding category where currently available products degrade in a relatively short period requiring repeat procedures. A significant opportunity exists to develop a permanent sub-dermal filler to address the deep tissue problems associated with facial restoration. Developing such a product is ULURU`s focus, which presents us with a unique opportunity to lead the development of a market segment which we project will expand into a market that exceeds $500 million.
As part of the acquisition of the topical product assets of Access Pharamceuticals, Inc., the strategic partnerships associated with the acquired technologies were transferred to ULURU. An extensive network of licenses is in place to globally market our approved products, these alliances include:
Product Partner Territory ------- ------- ---------OraDisc- Benzocaine Wyeth Consumer Healthcare North AmericaOraDisc- Amlexanox Discus Dental United States Zambon Europe Esteve Spain, Portugal, Greece Meda AB Scandinavia ProStrakan UK Ireland EpiTan Australia / New Zealand Orient Europharma Asia
In addition ULURU`s product Zindaclin, a once daily treatment for acne, has been licensed worldwide to ProStrakan. In turn, ProStrakan has established an extensive network of sub-licensees to market the product globally, including Fujisawa, for certain European markets, Pliva for the Central Eastern Europe region and numerous additional licensees for smaller territories.
The licenses currently in place provide ULURU with licensing revenue on the achievement of certain development and commercial milestones of in excess of $15 million. Additionally, ULURU will receive royalty payments in the range of 5-15% on all worldwide sales.
In addition to ULURU`s current OraDisc products, amlexanox for the prevention and treatment of canker sores and benzocaine for oral pain, ULURU has prioritized tooth whitening, cough and cold and desensitizing teeth as the lead consumer product developments. Also, ULURU plans to develop a range of prescription products utilizing OraDisc as a transmucosal delivery device. Supportive cancer care products and migraine relief are the initial development focus.
Commenting on the status of the company, Kerry P. Gray President and CEO of ULURU stated, "Establishing a commercial operation centered on our innovative nanoparticle aggregate technology, which presents us with the opportunity to market numerous products to meet unmet medical needs, is an exciting opportunity. We anticipate that we will continue to expand our network of strategic partners. We are currently working with a number of major pharmaceutical companies who are evaluating our technology and conducting consumer market research. Utilizing our technology portfolio, we believe it is possible to rapidly and cost-effectively develop value-added products. Given the numerous applications of the technology, we believe that we have the opportunity to significantly increase revenue from licensing activities."
ULURU Inc. is an emerging, specialty pharmaceutical company focused on the development of a portfolio of topical delivery technologies to proved patients and consumers with an improved clinical outcome through controlled delivery utilizing its innovative transmucosal delivery system and hydrogel nanoparticle aggregate technology.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and involve risks and uncertainties, including but not limited to statements made relating to the business prospects of ULURU Inc., the potential for ULURU Inc. to secure and maintain strategic partners, licensing revenues to be received under existing agreements and development of product candidates. These statements are subject to numerous risks and uncertainties
Trading Spotlight
...habe auch noch was gefunden:
http://www.americanbulls.com/StockPage.asp?CompanyTicker=OXF…
...ich beobachte weiter...
gruß jone...
http://www.americanbulls.com/StockPage.asp?CompanyTicker=OXF…
...ich beobachte weiter...
gruß jone...
Also Urulu hat wohl vor einiger Zeit die medizinsparte von Access Pharmaceuticals Inc. (auch im Internet zu finden) übernommen. Da OXFV Urulu übernommen hat, profitieren diese jetzt davon.
ULURU plans to establish a commercial organization to market products in niche areas including wound management, burn care and facial restoration and plans to out-license products that fall outside the strategic focus of the commercial organization. Commercial partners will be sought to market all products in international markets
Urulu plant im großen Stiel diverse Produkte an den markt zu bringen die normalerweise als sogen. nischenprodukte bezeichnet werden. Wundheilung, Verbrennungsbekopämpfung und Hautschutz. Desweiteren sollen auch für diese Produkte Lizenzen vergeben werden umd dann die produkte von Vertriebspartnern International vermarkten zu lassen.
Dieser Markt wird auf 3 Billionen $ geschätzt. Die Produkte bestehen auf Nano- Basis.
Developing such a product is ULURU`s focus, which presents us with a unique opportunity to lead the development of a market segment which we project will expand into a market that exceeds $500 million.
Allein der Markt für das Akne produkt ist 500 Mio $ Wert.
Diese produkte sind bereits im handel und folgende Vertriebspartner gehören dazu:
Product Partner Territory ------- ------- ---------OraDisc- Benzocaine Wyeth Consumer Healthcare North AmericaOraDisc- Amlexanox Discus Dental United States Zambon Europe EsteveSpainPortugal,Greece Meda AB Scandinavia ProStrakan UK Ireland EpiTan Australia / New Zealand Orient Europharma Asia
Naja so gut ich konnte............
ULURU plans to establish a commercial organization to market products in niche areas including wound management, burn care and facial restoration and plans to out-license products that fall outside the strategic focus of the commercial organization. Commercial partners will be sought to market all products in international markets
Urulu plant im großen Stiel diverse Produkte an den markt zu bringen die normalerweise als sogen. nischenprodukte bezeichnet werden. Wundheilung, Verbrennungsbekopämpfung und Hautschutz. Desweiteren sollen auch für diese Produkte Lizenzen vergeben werden umd dann die produkte von Vertriebspartnern International vermarkten zu lassen.
Dieser Markt wird auf 3 Billionen $ geschätzt. Die Produkte bestehen auf Nano- Basis.
Developing such a product is ULURU`s focus, which presents us with a unique opportunity to lead the development of a market segment which we project will expand into a market that exceeds $500 million.
Allein der Markt für das Akne produkt ist 500 Mio $ Wert.
Diese produkte sind bereits im handel und folgende Vertriebspartner gehören dazu:
Product Partner Territory ------- ------- ---------OraDisc- Benzocaine Wyeth Consumer Healthcare North AmericaOraDisc- Amlexanox Discus Dental United States Zambon Europe EsteveSpainPortugal,Greece Meda AB Scandinavia ProStrakan UK Ireland EpiTan Australia / New Zealand Orient Europharma Asia
Naja so gut ich konnte............
Oxford Ventures, Inc. (OTCBB: OXFV - http://finance.yahoo.com/q?s=OXFV.OB ) Oxford Ventures, Inc. announced that it has signed a definitive merger agreement to acquire ULURU Inc. ("ULURU"), a private Delaware company that focuses on advanced topical delivery of pharmaceutical agents. Separately, today ULURU announced the acquisition of the topical product assets of Access Pharmaceuticals, Inc. in a transaction valued at up to $20.7 million. Attached to this press release is a copy of the ULURU press release announcing the acquisition of the topical product assets.
Under the terms of the merger agreement, ULURU will become a wholly owned subsidiary of Oxford on the terms previously disclosed in our Form 8K filling with the Securities and Exchange Commission on September 13, 2005. In conjunction with the proposed acquisition, Oxford completed two financing transactions with an investor group including Highgate House Funds, Ltd. and Cornell Capital Partners LP. In the first transaction, Oxford has received a commitment for the sale of $15 million of secured convertible debentures, of which $13 million has been funded with the balance to be received upon the effectiveness of a registration statement filed with the Securities and Exchange Commission allowing for the resale of shares issued in connection with a Standby Equity Distribution Agreement. In the second financing, Oxford entered into a Standby Equity Distribution Agreement for up to $30 million.
Commenting on the recent developments, Daniel Leonard, President & CEO of Oxford, stated, "We have evaluated numerous opportunities for the company and believe that this series of transactions gives our shareholders the best opportunity to maximize returns. ULURU offers exciting potential as it has a developing revenue base and technologies from which significant product opportunities may be developed
Under the terms of the merger agreement, ULURU will become a wholly owned subsidiary of Oxford on the terms previously disclosed in our Form 8K filling with the Securities and Exchange Commission on September 13, 2005. In conjunction with the proposed acquisition, Oxford completed two financing transactions with an investor group including Highgate House Funds, Ltd. and Cornell Capital Partners LP. In the first transaction, Oxford has received a commitment for the sale of $15 million of secured convertible debentures, of which $13 million has been funded with the balance to be received upon the effectiveness of a registration statement filed with the Securities and Exchange Commission allowing for the resale of shares issued in connection with a Standby Equity Distribution Agreement. In the second financing, Oxford entered into a Standby Equity Distribution Agreement for up to $30 million.
Commenting on the recent developments, Daniel Leonard, President & CEO of Oxford, stated, "We have evaluated numerous opportunities for the company and believe that this series of transactions gives our shareholders the best opportunity to maximize returns. ULURU offers exciting potential as it has a developing revenue base and technologies from which significant product opportunities may be developed
Der Titel ist sehr aussichtsreich. Das Hoch bei der Fussionsnachricht war soweit ich weiß bei 1,5 Cent. Das könnten wir auch erreichen. Ich hab das alles zu spät mitgekriegt, steig aber auf jeden Fall noch mit ein.
Es gibt jetz drei Thread´s über OXFV:
Biomira, Nukem und Gony.
Wäre es nicht besser, in einem Thread weiter zu schreiben?
Dass es eine interessante Aktie sein könnte oder ist, dürfte jetzt doch einigen aufgefallen sein.
Es ginge konkreter und besser in einem Haupt-Thread.
Biomira, Nukem und Gony.
Wäre es nicht besser, in einem Thread weiter zu schreiben?
Dass es eine interessante Aktie sein könnte oder ist, dürfte jetzt doch einigen aufgefallen sein.
Es ginge konkreter und besser in einem Haupt-Thread.
...naja schön wäre ja, wenn mal einer unter den top 20 zu finden wäre 
...aber das kommt bestimmt erst wieder, wenn der wert mal wieder um 700 % steigt...oder noch besser "dausenddd"....
...der tag wird kommen...
...der tag wird kommen...
[posting]18.514.606 von jone77 am 30.10.05 21:21:44[/posting]Stimme dir wieder zu; jetzt laufe ich dir schon hinterher.
Sollte wirklich geändert werden!
Sollte wirklich geändert werden!
ok. einigen wir uns auf diesen thread ? 
...ja finde auch, relativ geringe mk. und keine milliarden von aktien.
...Interessant finde ich den chartverlauf der letzten 5 tage...volumen steigt wieder langsam an.
4o mio. am freitag
Ich denke, wenn wieder die Umsätze auf die 100 mio (bei steigender nachfrage)zugehen, gehts non stop über den cent...
...ja finde auch, relativ geringe mk. und keine milliarden von aktien.
...Interessant finde ich den chartverlauf der letzten 5 tage...volumen steigt wieder langsam an.
4o mio. am freitag
Ich denke, wenn wieder die Umsätze auf die 100 mio (bei steigender nachfrage)zugehen, gehts non stop über den cent...
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 240 | ||
| 113 | ||
| 107 | ||
| 73 | ||
| 57 | ||
| 39 | ||
| 37 | ||
| 36 | ||
| 34 | ||
| 31 |
| Wertpapier | Beiträge | |
|---|---|---|
| 27 | ||
| 23 | ||
| 19 | ||
| 18 | ||
| 18 | ||
| 18 | ||
| 17 | ||
| 17 | ||
| 16 | ||
| 16 |
